新型冠状病毒病-19:发病机制、健康影响及对策综述

Health Biotechnology and Biopharma Pub Date : 1900-01-01 DOI:10.22034/HBB.2020.08

M. Radhi, Fatima Malik Abood AL-Rubea, Iman Fadhel Abdul-Hussin, N. Hindi, R. AL-Jubori

{"title":"新型冠状病毒病-19:发病机制、健康影响及对策综述","authors":"M. Radhi, Fatima Malik Abood AL-Rubea, Iman Fadhel Abdul-Hussin, N. Hindi, R. AL-Jubori","doi":"10.22034/HBB.2020.08","DOIUrl":null,"url":null,"abstract":"The coronavirus disease-19 (COVID-19) signs mostly include fever and respiratory symptoms (unusual viral pneumonia by SARS-Coronaviruses 2 or SARS-CoV-2). The Receptor-Binding Domain (RBD) of COVID-19 and SARS-CoV are similar, causing cross-reactivity of anti-SARSCoV antibodies with associated spike protein, exerting promising implications for rapid development of vaccines and therapeutic antibodies against COVID-19. ACE2 is the SARS TMPRSS2 for spike (S) protein receptor for initiation of infection;hence, it is a target for pharmacological intervention. Furthermore, designing novel monoclonal antibodies binding specifically to COVID-19 RBD is essential. A viral S proteins (TMPRSS2) was proposed for clinical use by blocking the viral intake by cell.Copyright © 2020, Health Biotechnology and Biopharma. All rights reserved.","PeriodicalId":288173,"journal":{"name":"Health Biotechnology and Biopharma","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel coronavirus disease-19:An overviwe of pathogenesis, health influences and measures\",\"authors\":\"M. Radhi, Fatima Malik Abood AL-Rubea, Iman Fadhel Abdul-Hussin, N. Hindi, R. AL-Jubori\",\"doi\":\"10.22034/HBB.2020.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The coronavirus disease-19 (COVID-19) signs mostly include fever and respiratory symptoms (unusual viral pneumonia by SARS-Coronaviruses 2 or SARS-CoV-2). The Receptor-Binding Domain (RBD) of COVID-19 and SARS-CoV are similar, causing cross-reactivity of anti-SARSCoV antibodies with associated spike protein, exerting promising implications for rapid development of vaccines and therapeutic antibodies against COVID-19. ACE2 is the SARS TMPRSS2 for spike (S) protein receptor for initiation of infection;hence, it is a target for pharmacological intervention. Furthermore, designing novel monoclonal antibodies binding specifically to COVID-19 RBD is essential. A viral S proteins (TMPRSS2) was proposed for clinical use by blocking the viral intake by cell.Copyright © 2020, Health Biotechnology and Biopharma. All rights reserved.\",\"PeriodicalId\":288173,\"journal\":{\"name\":\"Health Biotechnology and Biopharma\",\"volume\":\"4 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Biotechnology and Biopharma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22034/HBB.2020.08\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Biotechnology and Biopharma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22034/HBB.2020.08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

冠状病毒病-19 (COVID-19)的症状主要包括发烧和呼吸道症状(由sars -冠状病毒2或SARS-CoV-2引起的异常病毒性肺炎)。COVID-19和SARS-CoV的受体结合域(RBD)相似，可引起抗sarscov抗体与相关刺突蛋白的交叉反应，这对快速开发COVID-19疫苗和治疗性抗体具有重要意义。ACE2是SARS刺突(S)蛋白启动感染的TMPRSS2受体，因此，它是药物干预的靶点。此外，设计特异性结合COVID-19 RBD的新型单克隆抗体至关重要。提出了一种病毒S蛋白(TMPRSS2)通过阻断细胞对病毒的摄取而用于临床。版权所有©2020，健康生物技术与生物制药。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel coronavirus disease-19:An overviwe of pathogenesis, health influences and measures

The coronavirus disease-19 (COVID-19) signs mostly include fever and respiratory symptoms (unusual viral pneumonia by SARS-Coronaviruses 2 or SARS-CoV-2). The Receptor-Binding Domain (RBD) of COVID-19 and SARS-CoV are similar, causing cross-reactivity of anti-SARSCoV antibodies with associated spike protein, exerting promising implications for rapid development of vaccines and therapeutic antibodies against COVID-19. ACE2 is the SARS TMPRSS2 for spike (S) protein receptor for initiation of infection;hence, it is a target for pharmacological intervention. Furthermore, designing novel monoclonal antibodies binding specifically to COVID-19 RBD is essential. A viral S proteins (TMPRSS2) was proposed for clinical use by blocking the viral intake by cell.Copyright © 2020, Health Biotechnology and Biopharma. All rights reserved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Health Biotechnology and Biopharma

CiteScore

0.60

自引率

0.00%

发文量